Genentech, Tercica win damages in patent suit
- Share via
From Bloomberg News
Insmed Inc. infringed three patents covering a treatment for abnormally short children, a jury said in a lawsuit brought by Genentech Inc. and Tercica Inc.
The jury in federal court in Oakland awarded San Francisco-based Genentech and Brisbane, Calif.-based Tercica $7.5 million in damages and a percentage of future sales of the treatment.
Richmond, Va.-based Insmed’s Iplex and Tercica’s product, called Increlex, are growth drugs used to treat about 6,000 short children.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
